<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fludrocortisone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fludrocortisone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fludrocortisone: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8455" href="/d/html/8455.html" rel="external">see "Fludrocortisone: Drug information"</a> and <a class="drug drug_patient" data-topicid="12477" href="/d/html/12477.html" rel="external">see "Fludrocortisone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866917"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Florinef</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052787"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Systemic</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span>;</li>
<li>
<span class="list-set-name">Mineralocorticoid</span></li></ul></div>
<div class="block don drugH1Div" id="F53462455"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afa687ed-131c-4dd7-b289-81195205fdfc">Congenital adrenal hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital</b>
<b> adrenal hyperplasia (salt losers):</b> Limited data available: Oral: Maintenance therapy: 0.05 to 0.2 mg daily in 1 or 2 divided doses; in newborns, doses as high as 0.4 mg/day may be necessary; use in combination with glucocorticoid therapy (eg, hydrocortisone) and sodium replacement therapy (Endocrine Society [Speiser 2018]; Sperling 2014).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F171970"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing should be individualized to lowest effective dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc5c86d4-2b20-490a-af5d-f75a4577de5d">Adrenal insufficiency, autoimmune; replacement therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, autoimmune (primary adrenal insufficiency, aldosterone deficiency component Addison disease); replacement therapy:</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.05 to 0.2 mg daily (Betterle 2002; Endocrine Society [Bornstein 2016]; Kliegman 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afa687ed-131c-4dd7-b289-81195205fdfc">Congenital adrenal hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia (salt losers) (eg, 21-hydroxylase deficiency):</b> Limited data available: <b>Note:</b> Use in combination with glucocorticoid therapy (eg, hydrocortisone); concurrent sodium replacement therapy may be required, particularly in young infants.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (actively growing): Oral: Usual range: 0.05 to 0.2 mg daily in 1 or 2 divided doses; doses as high as 0.3 mg/day may be necessary (AAP 2000; Endocrine Society [Speiser 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents (fully grown): Oral: 0.05 to 0.2 mg once daily (Endocrine Society [Speiser 2018]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110625"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51110626"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F171958"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8455" href="/d/html/8455.html" rel="external">see "Fludrocortisone: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Due to risk of hypokalemia, periodically monitor serum potassium during therapy; ensure adequate dietary potassium intake as appropriate (EFNS [Lahrmann 2006]; manufacturer's labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e27c0d04-e1e6-45b8-9a22-5029544cb68f">Adrenal insufficiency, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, primary (Addison disease):</b>
<b>Oral:</b> Initial: 0.05 to 0.1 mg once daily in the morning (in combination with glucocorticoid therapy). Usual maintenance dose: 0.05 to 0.2 mg once daily. If hypertension develops, dose reduction is suggested; an antihypertensive may be necessary if hypertension remains uncontrolled (ES [Bornstein 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5266f4e3-6235-4ab6-bb61-a9aaa38ce34c">Congenital adrenal hyperplasia, classic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia, classic (salt-losing adrenogenital syndrome):</b>
<b>Oral:</b> 0.05 to 0.2 mg/day in 1 or 2 divided doses (in combination with glucocorticoid therapy) (ES [Speiser 2018]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="197b65d3-18c8-49bc-8668-4d3943054759">Orthostatic hypotension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Orthostatic hypotension (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in conjunction with nonpharmacologic measures (eg, high-salt diet, adequate fluid intake, head-up tilt sleeping). Use with caution or avoid in patients with heart failure or low serum albumin (EFNS [Lahrmann 2006]; ESC [Brignole 2018]; Palma 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.05 to 0.1 mg once daily (Palma 2020; Schoffer 2007; Ten Harkel 1992). May adjust dose (eg, in 0.05 to 0.1 mg/day increments) at weekly intervals if needed based on response; usual dose range: 0.05 to 0.2 mg/day administered in 1 or 2 divided daily doses (Campbell 1976; EFNS [Lahrmann 2006]; Palma 2020; Schoffer 2007; Ten Harkel 1992; van Lieshout 2000). Doses &gt;0.2 mg/day have been associated with an increased risk of adverse effects without added benefit (EFNS [Lahrmann 2006]; Palma 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b2d2bcf-2892-4c38-946f-df5b5abfc5de">Postural orthostatic tachycardia syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postural orthostatic tachycardia syndrome (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.05 to 0.1 mg once daily. May increase slowly based on response and tolerability up to 0.1 to 0.2 mg/day (Bryarly 2019; Cheshire 2022; Mar 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9f759a1-600e-4dfb-8205-0b25031e6354">Septic shock, inadequate response to fluid resuscitation and vasopressor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock, inadequate response to fluid resuscitation and vasopressor therapy (adjunctive agent) (off-label use): Note:</b> Not widely used. If used, administer in combination with glucocorticoids in patients with ongoing vasopressor requirements (Annane 2002; Annane 2018; SSC [Evans 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.05 mg once daily for up to 7 days or until glucocorticoid is discontinued, whichever comes first. Discontinue fludrocortisone without a taper (Annane 2002; Annane 2018).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991101"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment likely to be necessary (eliminated mostly as inactive metabolites) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzability unknown: No supplemental dose or dosage adjustment likely to be necessary (eliminated mostly as inactive metabolites) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzability unknown: No dosage adjustment likely to be necessary (eliminated mostly as inactive metabolites) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (eliminated mostly as inactive metabolites) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (eliminated mostly as inactive metabolites) (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988389"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F56758654"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone growth inhibition</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids may inhibit bone growth (linear growth) in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21234507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21234507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; glucocorticoids decrease bone formation and increase bone resorption by a combination of factors, including decreasing calcium absorption and increasing calcium secretion; suppressing the somatotropic axis, resulting in suppressed growth hormone secretion; and increasing catabolism of the bone protein matrix and decreasing sex hormone production (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21234507','lexi-content-ref-32036458','lexi-content-ref-23381030','lexi-content-ref-23381030','lexi-content-ref-23381030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21234507','lexi-content-ref-32036458','lexi-content-ref-23381030','lexi-content-ref-23381030','lexi-content-ref-23381030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32036458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32036458'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fludrocortisone is associated with <b>hypertension</b> (most commonly supine systolic) and <b>heart failure </b>with reduced ejection fraction (HFrEF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729057','lexi-content-ref-29025750','lexi-content-ref-9014799','lexi-content-ref-28003914','lexi-content-ref-32979782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729057','lexi-content-ref-29025750','lexi-content-ref-9014799','lexi-content-ref-28003914','lexi-content-ref-32979782'])">Ref</a></span>). When using fludrocortisone to treat orthostatic hypotension (OH), it is important to consider comorbid conditions, as fludrocortisone patients have an increased risk of heart failure and all cause hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>). Supine hypertension was more common with autonomic failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>). In a study of older adults with OH, the incidence of hypertension and acute HFrEF was estimated at 6% and 11%, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9014799'])">Ref</a></span>). Development of HFrEF after initiation of fludrocortisone for treatment of adrenal insufficiency, although rare, is documented in 3 cases across all age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729057'])">Ref</a></span>). Children receiving fludrocortisone for congenital adrenal hyperplasia (CAH) have a higher incidence of hypertension (55%) compared to children not receiving fludrocortisone (31%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27105393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27105393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Transient increase in plasma volume due to potent mineralocorticoid activity promoting sodium retention, thereby expanding plasma volume and increasing cardiac afterload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729057','lexi-content-ref-29025750','lexi-content-ref-9014799','lexi-content-ref-25138826','lexi-content-ref-28003914','lexi-content-ref-32979782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729057','lexi-content-ref-29025750','lexi-content-ref-9014799','lexi-content-ref-25138826','lexi-content-ref-28003914','lexi-content-ref-32979782'])">Ref</a></span>). Sustained changes in blood pressure are from heightened sensitivity of alpha-adrenoreceptors and enhanced release of norepinephrine and angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750','lexi-content-ref-32979782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750','lexi-content-ref-32979782'])">Ref</a></span>). Long-term use may promote cardiac fibrosis, oxidative stress, and endothelial dysfunction that could affect cardiac remolding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varies; heart failure has been reported within 2 to 3 weeks after therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729057','lexi-content-ref-28003914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729057','lexi-content-ref-28003914'])">Ref</a></span>) and following long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>). In a study of older adults with OH, the mean time to development of hypertension and heart failure was 5 months and 7 months, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9014799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term treatment (independent of dose) in older adults with OH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9014799'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of HFrEF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of Addison disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729057','lexi-content-ref-25138826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729057','lexi-content-ref-25138826'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose in children &lt;8 years of age with CAH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27105393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27105393'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Electrolyte disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fludrocortisone is associated with <b>hypokalemia</b> and <b>hypomagnesemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>). In 2 studies of adults with orthostatic hypotension, the incidence of hypokalemia and hypomagnesemia was estimated at 24% to 50% and ~5%, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750','lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750','lexi-content-ref-9014799'])">Ref</a></span>). These electrolyte disturbances have the potential to further exacerbate underlying conditions (eg, arrhythmias), especially in those with heart failure with reduced ejection fraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750'])">Ref</a></span>). Hypomagnesemia was not reported in children receiving fludrocortisone for the treatment of primary adrenal insufficiency for an average of 6.5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33155789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33155789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Effect on the distal tubule in the kidney elicit sodium ion and water transport into the plasma, thereby increasing potassium and hydrogen ions into the urine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Veazie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Veazie.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varies; duration of therapy prior to development of hypokalemia ranges from within 1 week to several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29025750','lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29025750','lexi-content-ref-9014799'])">Ref</a></span>). In a study with older adults with orthostatic hypotension, the mean onset was 8 months (range: 2 to 21 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9014799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9014799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent amphotericin B, diuretics, or digoxin</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F171928"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomegaly, edema, heart failure (Grijalva 2017), hypertension (Bonfig 2015; Grijalva 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin rash, atrophic striae, diaphoresis, ecchymoses, facial erythema, hyperpigmentation (skin and nails), maculopapular rash, skin atrophy, subcutaneous atrophy, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cushing syndrome, growth retardation, hirsutism, HPA-axis suppression, hyperglycemia, hypokalemia (Grijalva 2017), hypokalemic alkalosis, menstrual disease, negative nitrogen balance, prediabetes</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, esophageal ulcer, pancreatitis, peptic ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, petechia, purpuric disease</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local acneiform eruptions</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amyotrophy, headache, intracranial hypertension (idiopathic), mental status changes (severe), myasthenia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Aseptic necrosis of femoral head, aseptic necrosis of humeral head, bone fracture (including pathological fracture and vertebral compression fracture), osteoporosis, steroid myopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Exophthalmos, glaucoma, subcapsular posterior cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (Grijalva 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Kaposi sarcoma (Goedert 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Burgdorff 2002, Pryse-Phillips 1984, Sieck 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema (Misra 2018)</p></div>
<div class="block coi drugH1Div" id="F171942"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to fludrocortisone or any component of the formulation; systemic fungal infections</p></div>
<div class="block war drugH1Div" id="F171925"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and kidney function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Because of the risk of adverse effects, use with caution in older adults; use with the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe illness).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878459"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Transient hypertrophic cardiomyopathy following treatment with dexamethasone and hydrocortisone has been reported in premature neonates (Alpert 1984; Jiang 2019; Röhr 2014; Vimala 2011).</p></div>
<div class="block foc drugH1Div" id="F171935"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg</p></div>
<div class="block geq drugH1Div" id="F171921"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F171945"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fludrocortisone Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg (per each): $0.75 - $0.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866918"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Florinef: 0.1 mg</p></div>
<div class="block adip drugH1Div" id="F53566745"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">In patients with salt-losing forms of congenital adrenogenital syndrome, use along with cortisone or hydrocortisone; fludrocortisone 0.1 mg has sodium retention activity equal to DOCA 1 mg</p></div>
<div class="block admp drugH1Div" id="F52612852"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to food; if GI upset, may take with food. Tablets may be crushed and mixed with about 1 teaspoon of water or soft food such as applesauce, chocolate syrup, jelly, or yogurt.</p></div>
<div class="block adm drugH1Div" id="F171939"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food; if GI upset, may take with food. For septic shock (off-label use), administer via nasogastric tube (Annane 2002; Annane 2018)</p></div>
<div class="block sts drugH1Div" id="F15509413"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F); avoid excessive heat. The Canadian labeling recommends to store at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F53566956"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison disease; treatment of salt-losing adrenogenital syndrome (or congenital adrenal hyperplasia) (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F171987"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Florinef may be confused with Fioricet, Fiorinal, Floranex, Florastor</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299344"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F171930"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineralocorticoid (Aldosterone) Receptor Antagonists: Fludrocortisone may diminish the therapeutic effect of Mineralocorticoid (Aldosterone) Receptor Antagonists. Mineralocorticoid (Aldosterone) Receptor Antagonists may diminish the therapeutic effect of Fludrocortisone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F171946"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Systemic use of mineralocorticoids/corticosteroids may require a diet with increased potassium, vitamins A, B<sub>6</sub>, C, D, folate, calcium, zinc, and phosphorus, and decreased sodium. With fludrocortisone, a decrease in dietary sodium is often not required as the increased retention of sodium is usually the desired therapeutic effect.</p></div>
<div class="block pri drugH1Div" id="F6472611"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted with fludrocortisone; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010). Fludrocortisone may be used to treat women during pregnancy who require therapy for congenital adrenal hyperplasia or primary adrenal insufficiency (Endocrine Society [Bornstein 2016; Speiser 2018]).</p></div>
<div class="block mopp drugH1Div" id="F53566940"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor blood pressure and signs of edema when patient is on chronic therapy; monitor serum electrolytes (eg, potassium, sodium, calcium), glucose, plasma renin activity. Monitor intraocular pressure (if therapy &gt;6 weeks), linear growth of pediatric patients (with chronic use), assess HPA suppression; monitor for evidence of infection  </p></div>
<div class="block pha drugH1Div" id="F171924"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Very potent mineralocorticoid with high glucocorticoid activity; used primarily for its mineralocorticoid effects. Promotes increased reabsorption of sodium and loss of potassium from renal distal tubules.</p></div>
<div class="block phk drugH1Div" id="F171941"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Plasma: ≥3.5 hours; Biological: 18 to 36 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Eliminated by the kidneys mostly as inactive metabolites (New Zealand datasheet).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038618"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cortilon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lonikan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Astonin h</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Florinef | Fludrocortisone medsurge</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aldocort</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cortinef</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Florinefe</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Astonin | Astonin h | Flocurtin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cortineff | Florinef | Fludrocortison</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Astonin h | Fludrocortison | Fludrocortison accord</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Navonel</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Astonin h | Cortineff | Florinef | Fluorinef</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Astonin h | Cortilon</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Astonin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adixone | Flucortac</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Florinef | Fludrocortison acetate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cortineff | Florinef</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Astonin h</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Floricot</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cortilon | Florinef</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Astonin h | Cortinef | Cortineff</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Astonin h</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cortinef | Cortineff | Florinef | Fludrocortison</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Floricot | Florinef</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Florinef | Fludrace | Fludrocortisonacetaat PCH</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cortineff</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Florinef | Fludrocortison acetate | Fludrocortisone</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Astonin h</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cortinef | Cortineff | Fludrocortisone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cortilon | Florinef acetat</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Astonin | Astonin h</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fludrocortison</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cortineff</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Astonin h</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cortinef | Cortineff</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Efenirol | Florinefe</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Florinef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12186608">
<a name="12186608"></a>Abraham E and Evans T, “Corticosteroids and Septic Shock (editorial),” <i>JAMA</i>, 2002, 288(7):886-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12186608/pubmed" id="12186608" target="_blank">12186608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6540865">
<a name="6540865"></a>Alpert BS. Steroid-induced hypertrophic cardiomyopathy in an infant. <i>Pediatr Cardiol</i>. 1984;5(2):117-118. doi:10.1007/BF02424962<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/6540865/pubmed" id="6540865" target="_blank">6540865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099616">
<a name="11099616"></a>American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics. Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. <i>Pediatrics</i>. 2000;106(6):1511-1518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/11099616/pubmed" id="11099616" target="_blank">11099616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938253">
<a name="28938253"></a>Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Crit Care Med</i>. 2017;45(12):2078-2088. doi:10.1097/CCM.0000000000002737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/28938253/pubmed" id="28938253" target="_blank">28938253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29490185">
<a name="29490185"></a>Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. <i>N Engl J Med</i>. 2018;378(9):809-818. doi:10.1056/NEJMoa1705716.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/29490185/pubmed" id="29490185" target="_blank">29490185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186604">
<a name="12186604"></a>Annane D, Sebille V, Charpentier C, et al, “Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,” <i>JAMA</i>, 2002, 288(7):862-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12186604/pubmed" id="12186604" target="_blank">12186604</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bahn RS (Chair), Burch HB, Cooper DS, et al, “Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,” <i>Thyroid</i>, 2011, 21(6):593-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/ 21510801/pubmed" id=" 21510801" target="_blank"> 21510801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12050123">
<a name="12050123"></a>Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. <i>Endocrine Rev</i>. 2002;23(3):327-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12050123/pubmed" id="12050123" target="_blank">12050123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26071487">
<a name="26071487"></a>Bonfig W, Roehl FW, Riedl S, et al; AQUAPE CAH Study Group. Blood pressure in a large cohort of children and adolescents with classic adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. <i>Am J Hypertens</i>. 2016;29(2):266-272. doi:10.1093/ajh/hpv087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/26071487/pubmed" id="26071487" target="_blank">26071487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi:10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562304">
<a name="29562304"></a>Brignole M, Moya A, de Lange FJ, et al; ESC Scientific Document Group. 2018 ESC guidelines for the diagnosis and management of syncope. <i>Eur Heart</i>
<i>J</i>. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/29562304/pubmed" id="29562304" target="_blank">29562304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12392389">
<a name="12392389"></a>Burgdorff T, Venemalm L, Vogt T, Landthaler M, Stolz W. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. <i>Ann Allergy Asthma Immunol</i>. 2002;89(4):425-428. doi:10.1016/S1081-1206(10)62046-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12392389/pubmed" id="12392389" target="_blank">12392389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30871704">
<a name="30871704"></a>Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural orthostatic tachycardia syndrome: JACC focus seminar. <i>J Am Coll Cardiol</i>. 2019;73(10):1207-1228. doi:10.1016/j.jacc.2018.11.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/30871704/pubmed" id="30871704" target="_blank">30871704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-769906">
<a name="769906"></a>Campbell IW, Ewing DJ, Clarke BF. Therapeutic experience with fludrocortisone in diabetic postural hypotension. <i>Br Med J</i>. 1976;1(6014):872-874. doi:10.1136/bmj.1.6014.872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/769906/pubmed" id="769906" target="_blank">769906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27729057">
<a name="27729057"></a>Campean R, Hasun M, Stöllberger C, et al. Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report. <i>J Med Case Rep</i>. 2016;10(1):281. doi:10.1186/s13256-016-1074-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/27729057/pubmed" id="27729057" target="_blank">27729057</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cheshire WP. Postural tachycardia syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779267">
<a name="11779267"></a>Coursin DB and Wood KE, “Corticosteroid Supplementation for Adrenal Insufficiency,” <i>JAMA</i>, 2002, 287(2):236-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/11779267/pubmed" id="11779267" target="_blank">11779267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS and Stewart PM, “Corticosteroid Insufficiency in Acutely Ill Patients,” <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21234507">
<a name="21234507"></a>Donatti TL, Koch VH, Takayama L, Pereira RM. Effects of glucocorticoids on growth and bone mineralization. <i>J Pediatr (Rio J)</i>. 2011;87(1):4-12. doi:10.2223/JPED.2052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/21234507/pubmed" id="21234507" target="_blank">21234507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33155789">
<a name="33155789"></a>Erbaş İM, Altincik SA, Çatli G, et al. Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency? <i>Turk J Med Sci</i>. 2021;51(1):231-237. doi:10.3906/sag-2008-167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/33155789/pubmed" id="33155789" target="_blank">33155789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Florinef (fludrocortisone acetate) [product monograph]. Montreal, Quebec, Canada: Paladin Labs; May 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fludrocortisone.2">
<a name="Fludrocortisone.2"></a>Florinef tablets. New Zealand datasheet. <a href="https://www.medsafe.govt.nz/profs/datasheet/f/Florineftab.pdf" target="_blank">https://www.medsafe.govt.nz/profs/datasheet/f/Florineftab.pdf</a>. Accessed June 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fludrocortisone.1">
<a name="Fludrocortisone.1"></a>Fludrocortisone Acetate Tablets, USP [prescribing information]. East Windsor, NJ: Novitium Pharma LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29025750">
<a name="29025750"></a>Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone Is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. <i>J Am Heart Assoc</i>. 2017;6(10):e006848. doi:10.1161/JAHA.117.006848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/29025750/pubmed" id="29025750" target="_blank">29025750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519925">
<a name="12519925"></a>Hotchkiss RS and Karl IE, “The Pathophysiology and Treatment of Sepsis,” <i>N Engl J Med</i>, 2003, 348(2):138-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/12519925/pubmed" id="12519925" target="_blank">12519925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9014799">
<a name="9014799"></a>Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. <i>Heart</i>. 1996;76(6):507-509. doi:10.1136/hrt.76.6.507. Erratum in: <i>Heart</i>. 1997;77(3):294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/9014799/pubmed" id="9014799" target="_blank">9014799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi:10.1111/cen.12592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31415406">
<a name="31415406"></a>Jiang J, Zhang J, Kang M, Yang J. Transient hypertrophic cardiomyopathy and hypertension associated with hydrocortisone in preterm infant: a case report. <i>Medicine (Baltimore)</i>. 2019;98(33):e16838. doi:10.1097/MD.0000000000016838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/31415406/pubmed" id="31415406" target="_blank">31415406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19900022">
<a name="19900022"></a>Kearney F and Moore A, “Pharmacological Options in the Management of Orthostatic Hypotension in Older Adults,” <i>Expert Rev Cardiovasc Ther</i>, 2009, 7(11):1395-1400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/19900022/pubmed" id="19900022" target="_blank">19900022</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16930356">
<a name="16930356"></a>Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. <i>Eur J Neurol</i>. 2006;13(9):930-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/16930356/pubmed" id="16930356" target="_blank">16930356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32036458">
<a name="32036458"></a>Lakatos P, Szili B, Bakos B, Takacs I, Putz Z, Istenes I. Thyroid hormones, glucocorticoids, insulin, and bone. <i>Handb Exp Pharmacol</i>. 2020;262:93-120. doi:10.1007/164_2019_314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/32036458/pubmed" id="32036458" target="_blank">32036458</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AYl. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21888303">
<a name="21888303"></a>Lanier JB, Mote MB, and Clay EC, “Evaluation and Management of Orthostatic Hypotension,” <i>Am Fam Physician</i>, 2011, 84(5):527-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/21888303/pubmed" id="21888303" target="_blank">21888303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA and Reed BR, "The Use of Dermatologic Drugs in Pregnancy and Lactation," <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al, "Use of Glucocorticoids in Pregnancy,"<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27105393">
<a name="27105393"></a>Maccabee-Ryaboy N, Thomas W, Kyllo J, et al. Hypertension in children with congenital adrenal hyperplasia. <i>Clin Endocrinol (Oxf)</i>. 2016;85(4):528-534. doi:10.1111/cen.13086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/27105393/pubmed" id="27105393" target="_blank">27105393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31412221">
<a name="31412221"></a>Mar PL, Raj SR. Postural orthostatic tachycardia syndrome: mechanisms and new therapies. <i>Annu Rev Med</i>. 2020;71:235-248. doi:10.1146/annurev-med-041818-011630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/31412221/pubmed" id="31412221" target="_blank">31412221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23381030">
<a name="23381030"></a>Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. <i>Nat Rev Endocrinol.</i> 2013;9(5):265-276. doi:10.1038/nrendo.2013.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/23381030/pubmed" id="23381030" target="_blank">23381030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29753556">
<a name="29753556"></a>Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. <i>Auton Neurosci.</i> 2018;215:28-36. doi:10.1016/j.autneu.2018.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/29753556/pubmed" id="29753556" target="_blank">29753556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30105362">
<a name="30105362"></a>Misra UK, Kalita J, Kumar M. Safety and efficacy of fludrocortisone in the treatment of cerebral salt wasting in patients with tuberculous meningitis: A randomized clinical trial. <i>JAMA Neurol</i>. 2018;75(11):1383-1391. doi:10.1001/jamaneurol.2018.2178. Erratum in: <i>JAMA Neurol</i>. 2018;75(11):1443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/30105362/pubmed" id="30105362" target="_blank">30105362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28003914">
<a name="28003914"></a>Mozolevska V, Schwartz A, Cheung D, Shaikh B, Bhagirath KM, Jassal DS. Addison's disease and dilated cardiomyopathy: A case report and review of the literature. <i>Case Rep Cardiol</i>. 2016;2016:4362514. doi:10.1155/2016/4362514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/28003914/pubmed" id="28003914" target="_blank">28003914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31996627">
<a name="31996627"></a>Palma JA, Kaufmann H. Management of orthostatic hypotension. <i>Continuum (Minneap Minn)</i>. 2020;26(1):154-177. doi:10.1212/CON.0000000000000816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/31996627/pubmed" id="31996627" target="_blank">31996627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32979782">
<a name="32979782"></a>Park JW, Okamoto LE, Shibao CA, Biaggioni I. Pharmacologic treatment of orthostatic hypotension. <i>Auton Neurosci</i>. 2020;229:102721. doi:10.1016/j.autneu.2020.102721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/32979782/pubmed" id="32979782" target="_blank">32979782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11091360">
<a name="11091360"></a>Park-Wyllie L, Mazzotta P, Pastuszak A, et al, "Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies," <i>Teratology</i>, 2000, 62(6):385-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/11091360/pubmed" id="11091360" target="_blank">11091360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745915">
<a name="14745915"></a>Pradat P, Robert-Gnansia E, Di Tanna GL, et al, “First Trimester Exposure to Corticosteroids and Oral Clefts,” <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/14745915/pubmed" id="14745915" target="_blank">14745915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6540393">
<a name="6540393"></a>Pryse-Phillips WE, Chandra RK, Rose B. Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis. <i>Neurology</i>. 1984;34(8):1119-1121. doi:10.1212/wnl.34.8.1119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/6540393/pubmed" id="6540393" target="_blank">6540393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3068012">
<a name="3068012"></a>Raisz LG. Hormonal regulation of bone growth and remodelling. <i>Ciba Found Symp</i>. 1988;136:226-238. doi:10.1002/9780470513637.ch14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/3068012/pubmed" id="3068012" target="_blank">3068012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32145864">
<a name="32145864"></a>Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. <i>Can J Cardiol.</i> 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/32145864/pubmed" id="32145864" target="_blank">32145864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6. Epub 2017 Jan 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24706463">
<a name="24706463"></a>Röhr SB, Sauer H, Gottschling S, et al. Non-neurological, steroid-related adverse events in very low birth weight infants: a prospective audit. <i>Swiss Med Wkly</i>. 2014;144:w13954. doi:10.4414/smw.2014.13954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/24706463/pubmed" id="24706463" target="_blank">24706463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8161268">
<a name="8161268"></a>Salem M, Tainsh RE Jr, Bromberg J, et al, “Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,” <i>Ann Surg</i>, 1994, 219(4):416-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/8161268/pubmed" id="8161268" target="_blank">8161268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17557339">
<a name="17557339"></a>Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. <i>Mov Disord</i>. 2007;22(11):1543-1549. doi:10.1002/mds.21428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/17557339/pubmed" id="17557339" target="_blank">17557339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25980576">
<a name="25980576"></a>Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. <i>Heart Rhythm</i>. 2015;12(6):e41-e63. doi:10.1016/j.hrthm.2015.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/25980576/pubmed" id="25980576" target="_blank">25980576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2102212">
<a name="2102212"></a>Sieck JO, al-Ohaly Y, Saour J, Khan M, Henriquez H. An allergic reaction to intravenous methylprednisolone administration. <i>Br J Clin Pract</i>. 1990;44(12):723-725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/2102212/pubmed" id="2102212" target="_blank">2102212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184957">
<a name="18184957"></a>Sprung CL, Annane D, Keh D, et al, “Hydrocortisone Therapy for Patients With Septic Shock,” <i>N Engl J Med</i>, 2008, 358(2):111-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/18184957/pubmed" id="18184957" target="_blank">18184957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1506810">
<a name="1506810"></a>Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. <i>J Intern Med</i>. 1992;232(2):139-145. doi:10.1111/j.1365-2796.1992.tb00563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/1506810/pubmed" id="1506810" target="_blank">1506810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20103758">
<a name="20103758"></a>The COIITSS Study Investigators, “Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults,” <i>JAMA</i>, 2010, 303(4):341-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/20103758/pubmed" id="20103758" target="_blank">20103758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10750642">
<a name="10750642"></a>van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. <i>Clin Auton Res</i>. 2000;10(1):35-42. doi:10.1007/BF02291388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/10750642/pubmed" id="10750642" target="_blank">10750642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Veazie.1">
<a name="Veazie.1"></a>Veazie S, Peterson K, Ansari Y, et al. Fludrocortisone for orthostatic hypotension. <i>Cochrane Database of Systematic Reviews</i>. 2017;12:CD012868. doi:10.1002/14651858.CD012868</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34655742">
<a name="34655742"></a>Velentza L, Zaman F, Sävendahl L. Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia. <i>Crit Rev Oncol Hematol.</i> 2021;168:103492. doi:10.1016/j.critrevonc.2021.103492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/34655742/pubmed" id="34655742" target="_blank">34655742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20045574">
<a name="20045574"></a>Vimala J, Prabhu A, Pavithran S, Kumar RN. Hydrocortisone induced hypertrophic cardiomyopathy. <i>Int J Cardiol</i>. 2011;150(3):e94-e95. doi:10.1016/j.ijcard.2009.12.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fludrocortisone-pediatric-drug-information/abstract-text/20045574/pubmed" id="20045574" target="_blank">20045574</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13306 Version 301.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
